Open AccessThe use of encainide in atrial fibrillation
Author(s) -
Vlay S. C.,
Reid P. R.
Publication year - 1984
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960070906
Subject(s) - medicine , atrial fibrillation , cardiology , paroxysmal atrial fibrillation , drug , refractory (planetary science) , anesthesia , pharmacology , physics , astrobiology
Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation. This approach represents an attempt to manage the pathophysiologic disturbance of atrial fibrillation by selection of a drug that would be expected to have specific effects on the conduction system.